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Objectives The goal of this study is to characterize resident cardiac stem cells (CSCs) and investigate their therapeutic effi-
cacy in myocardial infarction by molecular imaging methods.
Background CSCs have been isolated and characterized in vitro. These cells offer a provocative method to regenerate the
damaged myocardium. However, the survival kinetics and function of transplanted CSCs have not been fully
elucidated.
Methods CSCs were isolated from L2G85 transgenic mice (FVB strain background) that constitutively express both firefly
luciferase and enhanced green fluorescence protein reporter gene. CSCs were characterized in vitro and trans-
planted in vivo into murine infarction models. Multimodality noninvasive imaging techniques were used to as-
sess CSC survival and therapeutic efficacy for restoration of cardiac function.
Results CSCs can be isolated from L2G85 mice, and fluorescence-activated cell sorting analysis showed expression of
resident CSC markers (Sca-1, c-Kit) and mesenchymal stem cell markers (CD90, CD106). Afterwards, 5  105
CSCs (n  30) or phosphate-buffered saline control (n  15) was injected into the hearts of syngeneic FVB mice
undergoing left anterior descending artery ligation. Bioluminescence imaging showed poor donor cell survival by
week 8. Echocardiogram, invasive hemodynamic pressure-volume analysis, positron emission tomography imag-
ing with fluorine-18-fluorodeoxyglucose, and cardiac magnetic resonance imaging demonstrated no significant
difference in cardiac contractility and viability between the CSC and control group. Finally, postmortem analysis
confirmed transplanted CSCs integrated with host cardiomyocytes by immunohistology.
Conclusions In a mouse myocardial infarction model, Sca-1–positive CSCs provide no long-term engraftment and benefit to
cardiac function as determined by multimodality imaging. (J Am Coll Cardiol 2009;53:1229–40) © 2009 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.036g
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(ecent years have brought stem cell therapy for heart
isease to the forefront. Several clinical trials have shown
eneficial effects of stem cell transplantation to improve
ardiac function after myocardial infarction (MI) (1–3).
owever, the mechanism(s) behind this benefit is not
learly understood. Although numerous studies have sug-
ested the cardioprotective benefits from various stem cell
ypes, they also carry limitations including the potential of
umorigenicity with embryonic stem cells (4), arrhythmo-
rom the *Department of Radiology and Molecular Imaging Program (MIPS),
Department of Medicine, Division of Cardiology, ‡Department of Cardiothoracic
urgery, and the §Department of Comparative Medicine, Stanford University School
f Medicine, Stanford, California. This work was supported, in part, by grants from
he National Institutes of Health HL089027 (to Dr. Wu), the Burroughs Wellcome
oundation Career Award for Medical Scientists (to Dr. Wu), Stanford Cardiovas-
ular Institute (to Dr. Wu), and the Society of Nuclear Medicine Pilot Research
ward (to Dr. Li).g
Manuscript received September 26, 2008; revised manuscript received December 1,
008, accepted December 23, 2008.enicity with skeletal myoblasts (5), as well as existing
ontroversies surrounding transdifferentiation of bone
arrow-derived stem cells (6,7).
The identification of undifferentiated cells with stem
ell-like properties derived from the myocardium has re-
ewed the excitement in this field. A number of recent
tudies have confirmed the presence of cells bearing stem
ell markers in the myocardium, which were successfully
erminally differentiated into cell lineages that can benefit
yocardial function (8–12). A recent study even used
esident cardiac stem cells (CSCs) derived from human
yocardial biopsy specimens and injected them into
ice, showing engraftment and improved myocardial
unction (12).
We have previously described the L2G85 transgenic
ice, which constitutively express both the firefly luciferase
Fluc) and enhanced green fluorescence protein (eGFP)
enes (13,14). Cells derived from these mice provide the
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over time. Using the previously
described methods for CSC iso-
lation and proliferation (10), we
now provide in detail the survival
kinetics of transplanted CSCs
in infarcted murine hearts. In
contrast to previous studies
(9,10,12,15,16), our results sug-
gest that these CSCs do not
constitute long-term improve-
ment in myocardial function. We
also show definitive evidence via
bioluminescence imaging (BLI)
that the majority of these cells
are not viable by 8 weeks
post-transplantation.
Methods
Isolation and culture of CSCs.
Animal protocols were approved
by the Stanford University Ani-
mal Care and Use Committee.
The L2G85 transgenic mice of
FVB background with beta-actin
promoter driving Fluc-eGFP
have been described previously
(14,17). Normal adult female
FVB mice were used as recipient
controls. CSCs were isolated from
6- to 12-week-old L2G85 mice as
described with some modifications
(10,11). In brief, myocardial tissue
was cut into a 1- to 2-mm piece,
washed with Hanks’ balanced salt
solution (Invitrogen, Carlsbad,
California), and incubated with
0.1% collagenase II for 30 min at
37°C with frequent shaking. Cells
were then filtered through 100-m
mesh. The cells obtained were cul-
ured in Iscove’s modified Dulbecco’s medium supplemented
ith 10% fetal bovine serum (FBS) (Hyclone, Logan, Utah),
.1 mmol/l nonessential amino acids, 100 U/ml penicillin G,
00 g/ml streptomycin, 2 mmol/l glutamine, and 0.1 mmol/l
eta-mercaptoethanol. After 2 to 3 weeks, a population of
hase-bright cells appeared over the adhered fibroblast-like
ells. These phase-bright cells were collected by 2 washes
ith phosphate-buffered saline (PBS), and 1 wash with cell
issolution buffer (Gibco, Grand Island, New York) at room
emperature under microscopic monitoring, and subcultured
n poly-lysine-coated plates (BD Pharmingen, San Jose,
alifornia) with the same medium (Online Videos 1 and 2).
mmunofluorescence staining of cultured CSCs. The
Abbreviations
and Acronyms
BLI  bioluminescence
imaging
BM-MSC  bone marrow-
derived mesenchymal
stem cell
CSC  cardiac stem cell(s)
DAPI  4=6-diamidino-2-
phenylindole
DiI-ac-LDL  DiI acetylated
low-density lipoprotein
EF  ejection fraction
eGFP  enhanced green
fluorescence protein
FBS  fetal bovine serum
Fluc  firefly luciferase
FS  fractional shortening
%ID/g  injected dose per
gram of heart
LAD  left anterior
descending artery
LVEDd  left ventricular
end-diastolic diameter
LVESd  left ventricular
end-systolic diameter
MI  myocardial infarction
MRI  magnetic resonance
imaging
PBS  phosphate-buffered
saline
PET  positron emission
tomography
PV  pressure-volume
ROI  region of interest
RT-PCR  reverse
transcription-polymerase
chain reaction
[18F]-FDG  fluorine-
18-fluorodeoxyglucoseells were fixed with 4% paraformaldehyde and processed aor immunofluorescence with antibodies to Sca-1 (BD
harmingen) in situ. Briefly, cells were incubated with rat
ntimouse Sca-1 for 1 h at room temperature and incubated
ith goat antirat Alexa Fluor 594 (Invitrogen). 4=6-
iamidino-2-phenylindole (DAPI) was used for nuclear
ounterstaining.
low cytometry analysis. Fluorescence-activated cell sort-
ng (FACS) analysis of the bright cells and the cells
ubcultured on poly-lysine-coated plates were carried out,
nd the third passage of bone marrow-derived mesenchymal
tem cells (BM-MSCs) from L2G85 mice was used as
ontrol cells. The isolation and culturing techniques of
M-MSCs were similar to a previous report (18). Anti-
odies used in this study were phycoerythrin-conjugated
nti-CD34, CD29, CD90, CD44, CD54, Flk1, Sca-1,
llophycocyanin-conjugated anti-CD31 and c-Kit,
llophycocyanin-conjugated antirat IgG2a, and rat anti-
ouse CD62E, CD62P, Tie-2, CD144 (all from BD
harmingen). The stained cells were analyzed using BD
SR (BD Pharmingen). Dead cells stained by propidium-
odide were excluded from the analysis. Isotype-identical
ntibodies served as controls (BD Pharmingen). FlowJo
oftware (Tree Star Inc., Ashland, Oregon) was used for
ollowed data analysis.
n vitro differentiation of CSC. For cardiac and smooth
uscle differentiation, CSCs were cultured in poly-lysine-
oated plates in differentiation medium containing 35%
scove’s modified Dulbecco’s medium with 10% FBS/65%
ulbecco’s modified Eagle medium-Ham F-12 mix con-
aining 2% B27, 0.1 mmol/l 2-mercaptoethanol, 10 ng/ml
pidermal growth factor (R&D Systems Inc., Minneapolis,
innesota), 20 ng/ml basic fibroblast growth factor (R&D
ystems Inc.), 40 nmol/l cardiotrophin-1 (R&D Systems
nc.), 40 nmol/l thrombin (Sigma-Aldrich, St. Louis, Mis-
ouri), 100 U/ml penicillin G, 100 g/ml streptomycin, and
mmol/l glutamine (10). After 1 week, the cells were fixed
ith 4% paraformaldehyde and processed for immunofluo-
escence with antibodies specific to cardiac troponin T,
yocyte enhancer factor 2C, connexin 43, and -smooth
uscle actin (all from Santa Cruz Biotech, Santa Cruz,
alifornia) in situ. Briefly, cells were incubated with first
ntibody for 1 h at room temperature and incubated with
oat antirabbit or donkey antimouse Alexa Fluor 594.
API was used for nuclear counterstaining. For endothelial
ifferentiation, the phase-bright cells were cultured on
bronectin-coated plates with EGM-2 (Cambrex, Walk-
rsville, Maryland) with an extra 20 ng/ml of vascular
ndothelial growth factor. DiI acetylated low-density li-
oprotein (DiI-ac-LDL) uptake assay and Matrigel assay
ere used to confirm endothelial cell phenotype differenti-
tion. For DiI-ac-LDL uptake assay, cells were incubated
ith 10 g/ml of DiI-ac-LDL (Molecular Probes, Eugene,
regon) at 37°C for 6 h. After washing with PBS twice, the
lides were fixed and detected with fluorescence microscopy
s described (19,20). The formation of endothelial tubes was
ssessed by seeding cells in 24-well plates coated with
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or 12 h as described (19,20). For adipogenic differentiation,
he phase-bright cells were cultured in DMEM with 10%
BS, 100 U/ml penicillin G, 100 g/ml streptomycin, 2
mol/l glutamine, 1 mol/l dexamethasone, 10 g/ml
nsulin, 0.5 mmol/l isobulyl-1-methylxanthione, and 200
mol/l indomethacin for 2 weeks and medium was changed
very 3 days. The differentiated adipocytes were confirmed
y oil red staining and reverse transcription-polymerase
hain reaction (RT-PCR) analysis for peroxisome
roliferator-activated receptors gamma and lipoprotein
ipase expression. For osteogenic differentiation, the phase-
right cells were cultured in osteogenic differentiation me-
ium (Cambrex, Walkersville, Maryland; PT-3002) for 2 to
weeks and medium was changed every 3 days. The
steocyte differentiation was confirmed by Alizarin red S
taining and RT-PCR analysis for osteocalcin expression as
escribed (21).
I and cell delivery. All surgical procedures were per-
ormed on 8- to 10-week-old female FVB mice (Charles
iver Laboratories, Inc., Davis, California) by a single
xperienced micro-surgeon (G.H.). FVB mice were anes-
hetized with inhaled isoflurane (2% to 3%). Mice were
ntubated, ventilated, and anesthesia was maintained with
nhaled isoflurane (1% to 2.5%). A left thoracotomy was
erformed, and the pericardium was opened. The left
nterior descending artery (LAD) was permanently ligated
ith a 9-0 Ethilon suture (Ethicon Inc., Somerville, New
ersey) just distal to the level of the left atrium. Infarction
as visually confirmed by blanching of the anterior region of
he left ventricle along with dyskinesis. After 30 min, 5 
05 CSCs were injected intramyocardially into the peri-
nfarct zone at 2 different sites with a total volume of 20
l in each animal (n  30). Control animals received a
BS injection instead (n  15). For sham-operated
nimals (n  5), open thoracotomy was performed
ithout suturing of the LAD and without injection of
SCs or PBS. A thoracotomy tube was placed and lungs
ere re-expanded using positive pressure ventilation. The
hest cavity was closed in layers with 5-0 Vicryl suture
Ethicon Inc.), and the animal was gradually weaned from
he respirator. Once spontaneous respiration resumed, the
ndotracheal and thoracotomy tubes were removed, and the
nimals were placed in a temperature-controlled chamber
ntil they resumed full alertness and mobility.
ptical BLI of transplanted cell survival. BLI was per-
ormed on all animals (n  30 CSC, n  15 PBS, and n 
sham) using the IVIS 200 system (Xenogen, Alameda,
alifornia) by a blinded investigator (M.H.). A majority of
he animals were scanned on days 2, 7, 14, 21, 28, 49, and
6. After intraperitoneal injection of the reporter probe
-Luciferin (150 mg/kg), animals were imaged for 1 to 10
in. The same mice were imaged longitudinally for up to 8
eeks. Bioluminescence signals were quantified in units of
aximum photons per second per centimeter square perteridian (photons/s/cm2/sr) as described (19). Mardiac viability with fluorine-18-fluorodeoxyglucose
[18F]-FDG) positron emission tomography (PET) imag-
ng. Small animal microPET imaging (Vista system, GE
ealthcare, Chalfont St. Giles, United Kingdom) was per-
ormed in a subset of the animals (n  14 CSC and n  8
BS) on baseline (day 7) and days 2, 28, and 56 post-
peratively. Mice were fasted for 3 h before radioisotope
njection. Animals were then injected with 139  23 Ci
18F]-FDG via the tail vein. At 45 to 60 min after injection,
nimals were anesthetized with inhaled 2% isoflurane.
mages were performed, reconstructed by filtered back
rojection, and analyzed using image software Amide
Amide’s Medical Image Data Examiner, SourceForge,
nc., Mountain View, California) by a blinded investigator
A.L.). Three-dimensional regions of interest (ROIs) were
rawn encompassing the heart. For each ROI, counts/ml/
in were then converted to counts/g/min and divided by
he injected dose to obtain the image ROI derived [18F]-
DG percentage injected dose per gram of heart (% ID/g)
s described (22). To measure the myocardium infarction
ize, [18F]-FDG PET images were assembled into polar
aps (23). The size of perfusion defect was measured as the
yocardium with 50% of maximum activity and expressed
s percent total myocardium polar map by GE Healthcare
dvantage Workstation.
eft ventricular functional analysis with echocardiogram
nd pressure-volume (PV) acquisition. Echocardiography
as performed in all animals (n  30 CSC, n  15 PBS,
nd n  5 sham). A majority of the animals were scanned
n baseline (day7) and days 2, 28, and 56 post-operatively
y a blinded investigator (M.H.) using the Siemens-Acuson
equoia C512 system (Siemens Healthcare, Malvern, Penn-
ylvania) equipped with a multifrequency (8 to 14 MHz)
5L8 transducer. Animals were anesthetized with inhaled
% isoflurane. Analysis of M-mode images was performed.
eft ventricular end-diastolic diameter (LVEDd) and end-
ystolic diameter (LVESd) were measured and used to
alculate fractional shortening (FS) by the following for-
ula: FS  [LVEDd  LVESd]/LVEDd. At the end of
he study (week 8), invasive hemodynamic measurements
ere performed in a subset of the animals (n  5/group for
SC, PBS, and sham) as described (24). Briefly, after
idline neck incision, a conductance 1.4 conductance cath-
ter (Millar Instruments, Houston, Texas) was introduced
nto the left ventricle through the right carotid artery. After
tabilization, the signals were continuously recorded at a
ampling rate of 1,000/s using PV conductance system
oupled to a PowerLab/4SP analog to digital converter (AD
nstruments, Colorado Springs, Colorado). Data were an-
lyzed by using a cardiac PV analysis program (PVAN 3.4,
illar Instruments) and Chart/Scope Software (AD
nstruments).
ssessment of cardiac contractility with magnetic reso-
ance imaging (MRI). Please see the Online Supplemental
ethods section.
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Transplantation of Cardiac Resident Stem Cells April 7, 2009:1229–40istological analysis. After completion of the imaging pro-
ocols, all animals were sacrificed at week 8. For immunostain-
ng, explanted hearts (n  10 for CSC, n  5 for PBS, and
 2 for sham) were embedded into Tissue-Tek O.C.T.
ompound (Sakura Finetek USA Inc., Torrance, Califor-
ia), snap frozen in liquid nitrogen, and cut into transverse
ections at 5-m thickness. To track GFP-positive CSC-
erived cells and cardiomyocytes differentiation in hearts,
nti-GFP antibody (Invitrogen) and anti--sarcomeric ac-
in antibody (Sigma) were used. Alexa Fluor 488- and Fluor
94-conjugated secondary antibodies were applied appro-
riately. DAPI was used for nuclear counterstaining. To
Figure 1 Isolation and Culturing of CSCs
(A) Ventricular cells from L2G85 transgenic mice stained for Sca-1 (red) (I). After a p
cells (II). The phase-bright cells were collected, and Giemsa stain showed the cell
in vitro differentiation of phase-bright cells. Morphology of cardiac stem cells (CSC
(II). With cardiac differentiation medium, some CSCs can form cardiac sphere (arr
linear growth of cultured CSCs over a 1-month period. (D and E) Ex vivo imaging a
0.98). Also see Online Videos 1 and 2.etect microvascular density in the peri-infarct area, a rat
ntimouse CD31 (BD Pharmingen) and Alexa Fluor 647-
onjugated secondary antibody were used. The number of
apillary vessels was counted in 10 randomly selected areas
sing a fluorescence microscope (200 magnification). To
etect fibrosis in cardiac muscles, explanted hearts (n  10
or CSC, n  5 for PBS, and n  2 for sham) were fixed in
% paraformaldehyde, cut transversely, embedded in paraf-
n, and stained with Masson’s trichome (25). Five to 6
ections from apex to base were subjected to staining.
mages of each section were taken to calculate the fibrotic
nd nonfibrotic areas as well as ventricular and septal wall
nging from 1 to 3 weeks, phase-bright cells migrated over a layer of fibroblast-like
large nucleus (III). Scale bar  50 m (I, II),  2 m (III). (B) Subculture and
ultured in poly-D-lysine-coated plates and expressing green fluorescence protein
ith green fluorescence protein expression (III, IV). (C) Proliferation curves show
of CSCs shows increasing bioluminescence signals with cell numbers (r2 eriod ra
with a
s) (I) c
ow) w
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April 7, 2009:1229–40 Transplantation of Cardiac Resident Stem Cellshickness. The measurement of area of fibrosis was deter-
ined by Image J software (National Institutes of Health,
ethesda, Maryland) performed on 3 separate sections, and
he averages were used for statistical analysis.
tatistical analysis. Comparison of FS, ejection fraction
EF), cardiac viability, and infarction size between CSC
nd sham/PBS groups over time was done by 2-way
epeated measures analysis of variance (ANOVA) with
roup and day as factors, using a Greenhouse-Geisser
orrection for lack of sphericity. Comparison of end-
ystolic and -diastolic volume and pressure between CSC
nd sham/PBS groups was done by 2-way repeated
easures ANOVA with group and cardiac phase as
actors, using a Greenhouse-Geisser correction for lack of
phericity. Comparison of histological infarct size and
icrovascular density between PBS and CSC groups was
one by 2-tailed t test. Statistics were calculated using
PSS 14.0 (SPSS Inc., Chicago, Illinois). Descriptive
Figure 2 Characterization of Surface Markers in CSCs
Quantification by FACS analysis of cardiac stem cells (CSCs), phase-bright cells, a
(BM-MSCs) were used as a control. (A) CSCs express robust green fluorescence p
there was up-regulation of Sca-1. Left panels show Sca-1 antibody isotype control.
mesenchymal stem cells markers, CD29, CD90, CD44, and CD106. After subcultu
lated. Compared with BM-MSCs, CSCs express less CD54, but higher CD29 and Ctatistics included mean and standard error. Differences
ere considered significant at p values of 0.05.
esults
solation and culturing of CSCs. Explanted hearts were
ubjected to enzymatic digestion, cultured, and are composed
f Sca-1–positive cells (Fig. 1A). Phase bright spherical cells
hat spontaneously separated from the myocardium samples
ere identified after 2 to 3 weeks. These cells demonstrated a
igh nucleus-to-cytoplasm ratio and expressed robust GFP
Fig. 1B). The cells also demonstrated linear growth with
opulation doubling time of approximately 5 days (Fig. 1C),
imilar to previous studies (10,12,16). Importantly, assessment
f Fluc expression showed a linear correlation (r2  0.98)
etween the total cell numbers and the bioluminescence signals
Figs. 1D and 1E), which is needed for accurate tracking of cell
ate in subsequent in vivo imaging studies.
ir derived cells. Bone marrow mononuclear cell-derived mesenchymal stem cells
(GFP) both on phase-bright CSCs and their subcultures. After 2 to 3 passages,
uantitative analysis of cell markers expression by FACS. CSCs express high-level
ca-1 up-regulated, but c-Kit, CD34, CD31, and CD144 markers all down-regu-
All fluorescence-activated cell sorting experiments were performed in triplicate.nd the
rotein
(B) Q
ring, S
D90.
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Transplantation of Cardiac Resident Stem Cells April 7, 2009:1229–40haracterization of surface markers in CSCs. Previous
tudies have shown that Sca-1–expressing cells possess the
otential to differentiate into cardiomyocytes (10,11). Our
esults showed that 40.0  5.5% of the phase-bright cells
ere Sca-1 positive. After subculturing for 1 to 2 weeks,
ca-1 expression on CSCs was up-regulated close to 95%
Fig. 2A). In order to further characterize their cellular
henotypes, detailed flow cytometry analysis was performed.
verall, the subcultured group had higher expression of
esenchymal stem cell markers (CD29, CD90, CD44,
D106), but endothelial (CD31, CD34, CD144) and c-Kit
arkers were both down-regulated (Fig. 2B). Interestingly,
ompared with BM-MSCs, subcultured CSCs have a sim-
lar expression pattern, but express higher CD29 and CD90
nd lower CD54. CSCs isolated from normal syngeneic
VB mice also showed similar results (data not shown),
uggesting no significant effects on cellular characteristics
rom the stable expression of the Fluc-eGFP reporter gene.
verall, the expression of these markers in our CSCs is
imilar to previously published data (12,26).
ultipotent differentiation of CSCs. We next examined
he differentiation of CSCs into various cell types. Similar to
Figure 3 Multipotent Capacity of CSCs
(A) Cardiac and smooth muscle differentiation of cardiac stem cells (CSCs) in vitr
(cTnT), myocyte enhancer factor 2C (MEF-2C), connexin-43, and -smooth muscle
EGM-2 medium with 10 ng/ml vascular endothelial growth factor and showed endo
lipoprotein (II). Endothelial tube formation by differentiated CSCs after 12 h of pla
tures (IV). (C) Oil red staining and reverse transcription-polymerase chain reaction
lipase (LPL) expression shows adipogenic differentiation of the CSCs induced for 2
chain reaction analysis of osteocalcin expression show CSCs induced to differentither studies (10,21,27,28), these cells can differentiate into
ardiomyocytes and smooth muscle cells, as documented by
ositive staining for cardiac troponin T, connexin 43,
yocyte enhancer factor 2C, and -smooth muscle actin
Fig. 3A). After 7 days in differentiation medium, the cells
eveloped into clusters, and after 2 weeks they formed into
pherical collection of cells, some of which showed sponta-
eous contractility (Online Videos 1 and 2). In addition,
hese cells were capable of differentiating into endothelial
ells as demonstrated by DiI-ac-LDL uptake and Matrigel
ngiogenesis assays (Fig. 3B), into adipocytes as demon-
trated by oil red staining and RT-PCR analysis (Fig. 3C),
nd into osteoblasts as demonstrated by Alizarin red S
taining and RT-PCR analysis (Fig. 3D).
njection of CSCs into infarcted myocardium. Several
roups have reported that CSCs can proliferate indefinitely in
itro (10,21,27,28). This begs the question whether CSCs can
ave similar growth properties in vivo, and if so, whether this
ould lead to potential tumorigenesis. In order to address this
uestion, adult FVB mice were subjected to LAD artery
igation followed by injection with either 5  105 cultured
SCs (n  30) or PBS (n  15). Injection of CSCs into
unostaining of green fluorescence protein-positive CSCs with cardiac troponin T
SMA). (B) Endothelial differentiation of CSCs in vitro. The cells were cultured in
l differentiation by morphology (I) and uptake of DiI acetylated low-density
Matrigel (III) whereas undifferentiated CSCs cells do not form cord-like struc-
sis of peroxisome proliferator-activated receptors gamma (PPAR) and lipoprotein
s. (D) Alizarin red S staining of calcium and reverse transcription-polymerase
o osteoblasts.o. Imm
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April 7, 2009:1229–40 Transplantation of Cardiac Resident Stem Cellsnfarcted myocardium resulted in a robust biolumines-
ence signal at day 2. However, serial imaging of the
ame animals out to 8 weeks demonstrated a significant
ecay in the bioluminescence signal. When normalized to
esults from day 2, the percent bioluminescence signals
ere 6.7  0.5 at day 7, 3.9  0.8 at day 14, 1.7  0.2
t day 21, 1.4  0.1 at day 28, and 0.4  0.1 at day 56
Fig. 4). Control animals injected with PBS showed no
maging signals as expected.
ssessment of cardiac contractility and hemodynamic
tatus after CSC therapy. To date, only a few studies have
emonstrated that CSCs can improve cardiac function
10,21,27,28). In order to confirm these results, echocardio-
rams were performed at baseline, day 2, day 28, and day 56
ost-surgery (Figs. 5A and 5B). At day 2 after infarction,
here was a significant decrease in the FS in both the CSC
roup and the PBS group compared with that seen in
aseline, consistent with successful induction of MI. At days
8 and 56, there was a trend toward slight improvement in
he FS for both groups, but the difference was not statisti-
ally significant. These results were also confirmed in a
ubset of the animals that underwent cardiac MRI, which
howed no functional change in EF (Online Supplemental
Figure 4 Reporter Gene Imaging of CSC Fate After Transplanta
(A) A representative animal injected with 5  105 cardiac stem cells (CSCs) show
following 8 weeks. (B) Detailed quantitative analysis of signals from all animals tr
tion of percent donor cell survival plotted as % signal activity (normalized to day 2ig. 1). In addition, invasive hemodynamic parameters Phowed a decrease in EF for both CSC and control groups
ompared with that seen in the sham group (Online
upplemental Fig. 2). This was associated with higher left
entricular end-diastolic volume and left ventricular end-
ystolic volume in both groups compared with sham.
inally, as highlighted in the Online Supplemental Table
, there was no significant difference in other functional
arameters (e.g., cardiac output, stroke volume) between
SC transplanted mice and PBS control mice.
ssessment of cardiac viability after CSC therapy. In
ddition, we performed [18F]-FDG PET scans of the mice
t baseline, day 2, day 28, and day 56 post-surgery. This
echnique can be used to detect changes in cardiac viability
fter interventions in small animal models (29). At day 2
fter infarction, there was a significant reduction in cardiac
iability for both groups (20.2  4.9% ID/g for PBS and
0.8  4.2% ID/g for CSCs; p  0.001), consistent with
uccessful induction of MI. However, at day 28 and day 56,
here was no significant difference between the treatment
rm and the control group (Figs. 6A and 6B). Moreover,
nalysis of the [18F]-FDG PET images using polar-map
econstruction revealed no significant difference of infarc-
ion size between the CSC transplantation group and the
ificant bioluminescence activity at day 2, which decreases progressively over the
nted with CSCs. Signal activity is expressed as photons/s/cm2/sr. (C) Estima-
the 8-week period after transplantation. PBS  phosphate-buffered saline.tion
s sign
anspla
) overBS group (Figs. 6C and 6D).
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ent. Histological analysis of the myocardium was per-
ormed by both looking at thin sections of the gross specimen
nd via immunofluorescent microscopic examination. Micro-
copic examination showed the presence of GFP-positive cells
ithin myocardium at day 3 (Figs. 7A and 7B). At day 14,
SCs could differentiate into cardiomyocytes as con-
rmed by -smooth muscle actin and GFP double
tainings (Fig. 7C). However, this population became
ignificantly decreased when the tissues were examined at
ay 28 (Fig. 7D), which is also consistent with the
ecrease in bioluminescence signals over this period of
ime (Fig. 4). Finally, examination of the explanted
earts showed no significant difference in the infarct size
nd microvascular density between the 2 groups (Online
upplemental Fig. 3).
iscussion
n this study, we isolated cardiac resident stem cells from
2G85 transgenic mice that constitutively expressed Fluc-
GFP, enabling us to track stem cells by both noninvasive
maging and invasive histopathology. Upon culturing, we
emonstrated that these phase-bright cells up-regulated
ca-1 and expressed surface markers resembling mesenchy-
al stem cells. We also present evidence that molecular
Figure 5 Echocardiographic Evaluation of Cardiac Contractility
(A) Representative M-mode echocardiographic data of infarcted hearts receiving P
shortening (FS) and ejection fraction (EF) between the 2 groups 7 days before (bas
ligation. Abbreviations as in Figure 4.maging can be used to track CSCs survival in a murine vodel of MI. When injected directly into the infarcted
eart, these cells initially demonstrated viability by BLI. But
fter a period of 8 weeks, the majority of the imaging signals
ere no longer present, suggesting elimination from the
yocardium. Consequently, we found no significant phys-
ologic benefit from CSC therapy as determined from
ultiple parameters, including FS by echocardiogram, myo-
ardial glucose uptake by [18F]-FDG PET scan, EF by
RI, invasive PV loop analysis, and infarct size by his-
opathological assessment.
Recent works have documented the presence of a reser-
oir of stem and progenitor cells in the myocardium
8,10,16,21,30–32). These cells have been successfully iso-
ated and expanded ex vivo, and have been differentiated
nto cardiomyocytes, smooth muscle cells, and endothelial
ells (10,16,21,26,30–32). Previous works using CSCs have
lso demonstrated significant improvement in cardiac func-
ion after CSC injection, which was, in part, attributed to
he persistent engraftment of the injected CSCs into the
nfarct zone (9,12,16,33). A higher percentage of viable
yocardium within the infarct zone and improved EF were
emonstrated up to 5 weeks after cell transplantation (9). In
ontrast, BLI data from our study suggest that by week 8,
0.5% of the transplanted CSCs are still alive. By echocar-
iography and PET imaging, no significant changes were
bserved at day 28 and day 56 in cardiac contractility and
sus CSCs at day 2, week 4, and week 8. (B and C) Comparison of fractional
, 2 days, 28 days, and 56 days after left anterior descending coronary arteryBS ver
eline)iability.
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April 7, 2009:1229–40 Transplantation of Cardiac Resident Stem CellsAt present, we can only speculate that the discrepancy in
ndings may be attributed to differences in isolation tech-
iques (cardiosphere, side population), stem cell marker
xpression (c-Kit, Sca-1), donor cell sources (human, mice),
articular strains of mice used, or host animal models
nonreperfused LAD ligation, ischemia-reperfusion) (34).
rom the procedural standpoint, we cannot exclude that the
ossibility that our mice may have been oversedated (2%
soflurane) given the lower baseline FS values (35% to 40%)
Figure 6 [18F]-FDG PET Imaging of Cardiac Viability
(A) Representative image in a normal mouse heart and at days 2, 28, and 56 in i
group at days 28 and 56, respectively. (B) Detailed quantitative analysis of signal
ence of the FDG uptake (injected dose per gram of heart [% ID/g]) between the 2
(C and D) Representative polar map of the micropositron emission tomography (P
based on 50% thresholds. [18F]-FDG  fluorine-18-fluorodeoxyglucose; other abbrebserved compared with those in previous studies (35). This (ould have undermined the chances of detecting a small but
ignificant change between the 2 groups. From the trans-
enic model standpoint, it is possible that Fluc reporter gene
ilencing may have occurred and limited our ability to detect
urviving CSCs at late time points. However, a previous
tudy using hematopoietic stem cells isolated from these
ice was able to demonstrate complete reconstitution of the
rradiated bone marrow at late time points as detected by
LI, which argues against significant transgene silencing
d hearts receiving PBS versus CSCs. *p  0.46 and p  0.38 versus PBS
all animals transplanted with CSCs and PBS group. There is no significant differ-
. *p  0.31 and p  0.40 versus PBS group at days 28 and 56, respectively.
ages obtained from mice treated with PBS versus CSC. Measurements are
s as in Figure 4.nfarcte
s from
groups
ET) im
viation17). From the technical standpoint, BLI is limited to small
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Transplantation of Cardiac Resident Stem Cells April 7, 2009:1229–40nimal imaging as the low-energy photons (2 to 3 eV) can
ecome attenuated within deeper tissues (e.g., heart) com-
ared with more superficial locations (e.g., skeletal muscles).
t present, a conservative estimate of minimal detectable
ell number by BLI is 1,000 in the heart versus 100 in
he leg (14). Finally, from the instrumentation standpoint, it
s plausible that the image resolution (1.5 mm3) and
etection sensitivity (109 to 1012 mol/l) of the small
nimal microPET scanner is still insufficient to distinguish
ubtle but significant differences in [18F]-FDG uptake
etween the 2 groups. Thus, additional studies will be
eeded in the future to further examine each of these
ariables separately.
Just as the mechanism of stem cells exerting benefit on
yocardial function remains to be fully elucidated, the
echanism of their elimination over time also remains
Figure 7 Tracking of Grafted CSCs by Immunofluorescence
(A and B) Cardiac stem cells (CSCs) within the recipient myocardium 3 days after
ferentiate and integrate with host myocardium as confirmed by green fluorescence
ferentiate into cardiomyocytes as confirmed by -SA and GFP double stainings (C)
examined at day 28 (D), which is also consistent with the decrease in bioluminesoorly understood. The pattern of acute donor cell death teen in our CSC transplantation is also consistent with
revious studies showing poor donor cell survival after
ransplantation of neonatal cardiomyocytes (36), mesen-
hymal stem cells (37), bone marrow mononuclear cells
14), and human embryonic stem cell-derived cardiomy-
cytes (38). A number of culprits may be involved,
ncluding inflammation, ischemia, apoptosis, anoikis, and
utophagy, and may all play contributory roles. Further-
ore, the myocardial milieu in vivo is in stark contrast to
he rich nutrients and oxygen concentration that have
een optimized for their cell culturing, growth, and
xpansions in vitro. It is interesting to note historically
hat myoblast transplantation as a potential cell-based
herapy for patients with Duchenne muscular dystrophy
et with disappointing failures in the 1990s (39). One of
he main reasons was acute donor cell death after transplanta-
on shown at low and high magnification. (C and D) Transplanted CSCs can dif-
in (GFP) and -sarcomeric actin (SA) double staining. At day 14, CSCs could dif-
ver, this population became significantly decreased when the tissues were
signals over this period of time. Scale bar  100 m (A), 20 m (B to D).injecti
prote
. Howe
cenceion. Future clinical studies aimed at transplanting CSCs in
p
a
b
e
p
s
p
f
n
m
p
e
T
i
b
i
a
C
I
t
C
f
c
u
i
r
f
n
R
S
S
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
1239JACC Vol. 53, No. 14, 2009 Li et al.
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cute donor cell death.
Despite the limitation of acute donor stem cell death,
oth animal and clinical studies have suggested beneficial
ffects after transplantation of various stem cell types (40),
erhaps acting through paracrine pathways (41). Thus,
trategies aimed at prolonging cell survival (and, hence,
rolonging paracrine activation) may lead to even more
avorable results. To that extent, the application of bioengi-
eering methods (42), pro-survival cocktails (43), or genetic
odification (44), rather than direct stem cell injection, may
rove to be a more viable approach for achieving long-term
ngraftment in the future. Encouragingly, a recent study by
illmanns et al. (45) showed that CSCs activated with
nsulin-like growth factor 1 and hepatocyte growth factor
efore their injection into infarcted sites had significantly
mproved cell survival rate and were able to form conductive
rterioles and capillaries in the host myocardium.
onclusions
n summary, our study demonstrates that imaging can be used
o monitor CSC fate noninvasively in living animals and that
SC transplantation provides no significant benefits to cardiac
unction in a mouse MI model. As the field of CSC therapy
ontinues to mature, it is critical to better understand the
nderlying mechanism of the treatment modality, and to
dentify the potential pitfalls of the therapy before its incorpo-
ation into the clinical realm (1). Although a stem cell source
rom the heart is of tremendous potential, cautious optimism is
ecessary before full clinical use of these cells.
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